^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Chong Kun Dang, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    2ms
    AFLIWEST: Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    2ms
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=388, Completed, Genentech, Inc. | Trial completion date: Apr 2027 --> Jun 2026 | Trial primary completion date: Apr 2027 --> May 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=304, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    2ms
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Completed, Sam Chun Dang Pharm. Co. Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    3ms
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    3ms
    A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=304, Not yet recruiting, Amgen
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P1/2, N=139, Active, not recruiting, Alcon Research | Trial primary completion date: Oct 2027 --> May 2027
    Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    3ms
    ARTEMIS: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=311, Active, not recruiting, Adverum Biotechnologies, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P1/2, N=139, Active, not recruiting, Alcon Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=188, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema (clinicaltrials.gov)
    P=N/A, N=3000, Active, not recruiting, Bayer | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial primary completion date • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    3ms
    A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)